 Drug Synergism
"Drug Synergism" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The action of a drug in promoting or enhancing the effectiveness of another drug.
| Descriptor ID |
D004357
|
| MeSH Number(s) |
G07.690.812.240.477 G07.700.680.240.477
|
| Concept/Terms |
Drug Synergism- Drug Synergism
- Drug Synergisms
- Synergism, Drug
- Synergisms, Drug
Drug Potentiation- Drug Potentiation
- Drug Potentiations
- Potentiation, Drug
- Potentiations, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Synergism".
Below are MeSH descriptors whose meaning is more specific than "Drug Synergism".
This graph shows the total number of publications written about "Drug Synergism" by people in this website by year, and whether "Drug Synergism" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 1 | 1 | | 1983 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1985 | 0 | 2 | 2 | | 1987 | 0 | 1 | 1 | | 1988 | 0 | 6 | 6 | | 1989 | 0 | 3 | 3 | | 1990 | 0 | 3 | 3 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 3 | 3 | | 1993 | 0 | 5 | 5 | | 1994 | 0 | 3 | 3 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 5 | 5 | | 1998 | 0 | 8 | 8 | | 1999 | 0 | 3 | 3 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 7 | 7 | | 2002 | 0 | 11 | 11 | | 2003 | 0 | 6 | 6 | | 2004 | 0 | 8 | 8 | | 2005 | 1 | 6 | 7 | | 2006 | 0 | 7 | 7 | | 2007 | 0 | 4 | 4 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 7 | 7 | | 2012 | 1 | 6 | 7 | | 2013 | 0 | 7 | 7 | | 2014 | 0 | 5 | 5 | | 2015 | 0 | 11 | 11 | | 2016 | 0 | 8 | 8 | | 2017 | 1 | 7 | 8 | | 2018 | 0 | 7 | 7 | | 2019 | 0 | 3 | 3 | | 2020 | 0 | 6 | 6 | | 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Synergism" by people in Profiles.
-
Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, Huddle BC, Low J, Blankenship KB, Wang Y, Gordon B, Archer P, Brady SW, Natarajan S, Posgai MJ, Schuetz J, Miller D, Kalathur R, Chen S, Connelly JP, Babu MM, Dyer MA, Pruett-Miller SM, Freeman BB, Chen T, Godley LA, Blanchard SC, Stewart E, Easton J, Geeleher P. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021 11 09; 12(1):6468.
-
Khomtchouk KM, Joseph LI, Khomtchouk BB, Kouhi A, Massa S, Xia A, Koliesnik I, Pletzer D, Bollyky PL, Santa Maria PL. Treatment with a neutrophil elastase inhibitor and ofloxacin reduces P. aeruginosa burden in a mouse model of chronic suppurative otitis media. NPJ Biofilms Microbiomes. 2021 04 06; 7(1):31.
-
Eisfelder BJ, Saygin C, Wynne J, Colton MW, Fischietti M, Beauchamp EM, Cheng JX, Odenike O, Roboz G, Alachkar H, Stock W. OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia. Blood Cancer J. 2021 03 03; 11(3):48.
-
Pan C, Duan H, Wu Y, Zhu C, Yi C, Duan Y, Lu D, Guo C, Wu D, Wang Y, Fu X, Xu J, Chen Y, Luo M, Tian W, Pan T, Xu W, Zhang S, Huang J. Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. Int J Oncol. 2020 10; 57(4):939-955.
-
Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
-
Chargari C, Levy A, Paoletti X, Soria JC, Massard C, Weichselbaum RR, Deutsch E. Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research. Clin Cancer Res. 2020 09 15; 26(18):4723-4736.
-
Zhong Y, Sun R, Geng Y, Zhou Q, Piao Y, Xie T, Zhou R, Shen Y. N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy. Biomater Sci. 2020 Mar 17; 8(6):1726-1733.
-
Nazari F, Oklejas AE, Nör JE, Pearson AT, Jackson TL. In Silico Models Accurately Predict In Vivo Response for IL6 Blockade in Head and Neck Cancer. Cancer Res. 2020 04 01; 80(7):1451-1460.
-
Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, Whiteson KL, Gustafson HH, Slade DJ, Schmidt TM, Walther-Antonio MRS, Korem T, Webb-Robertson BM, Styczynski MP, Johnson WE, Jobin C, Ridlon JM, Koh AY, Yu M, Kelly L, Wargo JA. The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View. Trends Cancer. 2020 03; 6(3):192-204.
-
Galliverti G, Wullschleger S, Tichet M, Murugan D, Zangger N, Horton W, Korman AJ, Coussens LM, Swartz MA, Hanahan D. Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunol Res. 2020 01; 8(1):131-145.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|